Evidence map›Paper›PMID 33173945›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

Serum Soluble Receptor for Advanced Glycation End Products in Infants With Bronchiolitis: Associations With Acute Severity and Recurrent Wheeze.

Jason T Patregnani, Michimasa Fujiogi, Carlos A Camargo, Bonnie A Brooks, Claire E Hoptay, Jonathan M Mansbach, Stephen J Teach, Robert J Freishtat, Kohei Hasegawa

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Soluble receptor for advanced glycation end products (sRAGE) and asthma: Mendelian randomisation study.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Jason T PatregnaniDivision of Cardiac Critical Care Medicine, Children's National Hospital, Washington, DC, USA.ORCID 0000-0002-7153-3352
Michimasa FujiogiDepartment of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Carlos A CamargoDepartment of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Bonnie A BrooksDivision of Cardiac Critical Care Medicine, Children's National Hospital, Washington, DC, USA.
Claire E HoptayDepartment of Genomics and Precision Medicine, George Washington University, Washington, DC, USA.
Jonathan M MansbachDivision of General Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Stephen J TeachDivision of Emergency Medicine, Children's National Hospital, Washington, DC, USA.
Robert J FreishtatDepartment of Genomics and Precision Medicine, George Washington University, Washington, DC, USA.
Kohei HasegawaDepartment of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Children's National · USHarvard University · USBoston Children's Hospital · USGeorge Washington University · USTufts University · US

Funding

Host genetics, early-life microbiome, and childhood asthma: MARC-43 BostonUH3OD023253 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CARLOS ARTURO CAMARGO · 2018 to 2026
$12.1M
Nasal microRNA during bronchiolitis and age 6y asthma phenotypes: MARC-35 cohortR01AI127507 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CAMARGO, CARLOS ARTURO, FREISHTAT, ROBERT J · 2017 to 2021
$8.0M
Host genetics, early-life microbiome, and childhood asthma: MARC-43 BostonUG3OD023253 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CAMARGO, CARLOS ARTURO · 2016 to 2024
$6.8M
Airway dual-transcriptomics in bronchiolitis and risk of asthma: MARC-35 cohortR01AI137091 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HASEGAWA, KOHEI · 2018 to 2022
$4.3M
Airway metagenome & metabolome in bronchiolitis and risk of asthma: MARC-35 cohortR01AI134940 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HASEGAWA, KOHEI · 2018 to 2022
$4.0M
K12 Career Development Program: Omics of Pediatric Lung Diseases in DCK12HL119994 · NHLBI · CHILDREN'S RESEARCH INSTITUTE · PI FREISHTAT, ROBERT J · 2013 to 2017
$1.3M
NHLBI NIH HHS K12 HL119994NIAID NIH HHS R01 AI127507NIAID NIH HHS R01 AI134940NIAID NIH HHS R01 AI137091NIH HHS UG3 OD023253NIH HHS UH3 OD023253
6 · The paper itself

Abstract

backgroundAlthough bronchiolitis contributes to substantial acute (eg, intensive care use) and chronic (eg, recurrent wheeze) morbidities in young children, the pathobiology remains uncertain. We examined the associations of serum soluble receptor for advanced glycation end products (sRAGE) with acute and chronic morbidities of bronchiolitis including recurrent wheeze.

methodsA multicenter, multiyear, cohort study of infants hospitalized for bronchiolitis was analyzed. We measured the serum sRAGE level at hospitalization and its association with intensive care use (use of mechanical ventilation and/or admission to the intensive care unit) and development of recurrent wheeze by age 3 years. We performed causal mediation analysis to estimate indirect (mediation) and direct effects of sRAGE on recurrent wheeze.

resultsIn 886 infants with bronchiolitis, the median age was 2.9 months. Overall, 15% underwent intensive care and 32% developed recurrent wheeze. In multivariable modeling adjusting for 11 confounders, a higher presenting sRAGE level was associated with lower risk of intensive care (odds ratio for each 1-log increment, 0.39; 95% confidence interval [CI], .16 -.91; P = .03) and significantly lower rate of recurrent wheeze (hazard ratio [HR], 0.58; 95% CI, .36 -.94; P = .03). In mediation analysis, the direct effect was significant (HR, 0.60; 95% CI, .37 -.97; P = .04), while the indirect effect was not (P = .30).

conclusionsSerum sRAGE levels were inversely associated with acute and chronic morbidities of bronchiolitis. The effect of sRAGE on development of recurrent wheeze is potentially driven through pathways other than acute severity of bronchiolitis.

Indexed as

BronchiolitisGlycation End Products, AdvancedBiomarkersChildChild, PreschoolCohort StudiesHospitalizationHumansInfantReceptor for Advanced Glycation End ProductsBiomarkersGlycation End Products, AdvancedReceptor for Advanced Glycation End Productsadvancedasthmabronchiolitiscohortglycation end productsmediationpediatrics

Identifiers

PMID33173945
PMCPMC8563181
OpenAlexW3102586220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.